News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website

 

Factors Affecting Survival in Glioblastoma: A 10-year Single-Center Experience From Saudi Arabia

Al's Comment:

 I posted this to show that even though we sometimes feel that no progress is being made, we need to remember how bad this disease is and appreciate what we do have.  This report shows that the average survival in this hospital in Saudia Arabia (from 2005 to 2015) is only 8 months!  They probably picked 2005 because that is when Temozolomide was approved for Glioblastoma, although it was commonly used here in the USA for Glioblastomas since 1999 when it was approved for anaplastic astrocytoma. (My dad used it for a gbm in 1999!).  They do not mention Optune, even though it was approved in 2011.


Posted on: 06/02/2020

Factors Affecting Survival in Glioblastoma: A 10-year Single-Center Experience From Saudi Arabia

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740